{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:22:20Z","timestamp":1773966140232,"version":"3.50.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014355","name":"Nirma University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014355","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jsbmb.2025.106934","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T19:14:22Z","timestamp":1767208462000},"page":"106934","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Increased TGF-\u03b2 signaling during antiestrogen therapy in triple-negative breast cancer cells"],"prefix":"10.1016","volume":"257","author":[{"given":"Nandani","family":"Dharwal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepshikha","family":"Rathore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirali","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6029-6515","authenticated-orcid":false,"given":"Heena V.","family":"Dave","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsbmb.2025.106934_bib1","unstructured":"\u201cBreast cancer.\u201d Accessed: May 28, 2025. [Online]. Available: \u3008https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer\u3009."},{"issue":"3","key":"10.1016\/j.jsbmb.2025.106934_bib2","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3390\/cancers14030539","article-title":"Multifaceted interplay between hormones, growth factors and hypoxia in the tumor microenvironment","volume":"14","author":"Lappano","year":"2022","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.jsbmb.2025.106934_bib3","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.3390\/ijms24044002","article-title":"Crosstalk of inflammatory cytokines within the breast tumor microenvironment","volume":"24","author":"Habanjar","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.jsbmb.2025.106934_bib4","article-title":"Prognostic significance of ER-to-PR difference in ER+\/HER2- early breast cancer","volume":"14","author":"Wu","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.jsbmb.2025.106934_bib5","first-page":"1","article-title":"Tamoxifen and oxidative stress: an overlooked connection","volume":"12","author":"Ahmed","year":"2021","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.jsbmb.2025.106934_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2021.109602","article-title":"Metabolic reprograming confers tamoxifen resistance in breast cancer","volume":"347","author":"Mishra","year":"2021","journal-title":"Chem. Biol. Inter."},{"issue":"10","key":"10.1016\/j.jsbmb.2025.106934_bib7","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.3390\/cancers15102689","article-title":"Comparison of clinical subtypes of breast cancer within the claudin-low molecular cluster reveals distinct phenotypes","volume":"15","author":"Voutsadakis","year":"2023","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.jsbmb.2025.106934_bib8","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3390\/pharmaceutics15071796","article-title":"Triple negative breast cancer treatment options and limitations: future outlook","volume":"15","author":"Sarno","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jsbmb.2025.106934_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107101","article-title":"Roles of TGF-\u03b2 signaling pathway in tumor microenvirionment and cancer therapy","volume":"89","author":"Zhao","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"46","key":"10.1016\/j.jsbmb.2025.106934_bib10","doi-asserted-by":"crossref","first-page":"42908","DOI":"10.1074\/jbc.M105316200","article-title":"Cross-talk between transforming growth Factor-\u03b2 and estrogen receptor signaling through Smad3","volume":"276","author":"Matsuda","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jsbmb.2025.106934_bib11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cytogfr.2021.09.005","article-title":"Role of TGF-\u03b2 signaling in the mechanisms of tamoxifen resistance","volume":"62","author":"Babyshkina","year":"2021","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.jsbmb.2025.106934_bib12","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1749-6632.2002.tb04104.x","article-title":"Antiestrogenic regulation of transforming growth factor beta receptors I and II in human breast cancer cells","volume":"963","author":"Buck","year":"2002","journal-title":"Ann. N. Y Acad. Sci."},{"issue":"8","key":"10.1016\/j.jsbmb.2025.106934_bib13","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1007\/s00018-013-1376-3","article-title":"Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy","volume":"71","author":"Zhou","year":"2013","journal-title":"Cell Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.jsbmb.2025.106934_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-023-01497-3","article-title":"Recent advances in targeted strategies for triple-negative breast cancer","volume":"16","author":"Zhu","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"21","key":"10.1016\/j.jsbmb.2025.106934_bib15","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.3390\/cancers14215206","article-title":"Molecular mechanisms of anti-estrogen therapy resistance and novel targeted therapies","volume":"14","author":"Ozyurt","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.jsbmb.2025.106934_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2021.111322","article-title":"Mechanisms of endocrine therapy resistance in breast cancer","volume":"532","author":"Rasha","year":"2021","journal-title":"Mol. Cell Endocrinol."},{"issue":"3","key":"10.1016\/j.jsbmb.2025.106934_bib17","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.3390\/curroncol28030168","article-title":"Current landscape of targeted therapy in hormone receptor-positive and HER2-negative breast cancer","volume":"28","author":"Andrahennadi","year":"2021","journal-title":"Curr. Oncol."},{"issue":"4","key":"10.1016\/j.jsbmb.2025.106934_bib18","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/oncolo\/oyac281","article-title":"Therapeutic role of tamoxifen for triple-negative breast cancer: leveraging the interaction between ER\u03b2 and mutant p53","volume":"28","author":"Scarpetti","year":"2023","journal-title":"Oncologist"},{"issue":"15","key":"10.1016\/j.jsbmb.2025.106934_bib19","doi-asserted-by":"crossref","first-page":"7326","DOI":"10.3390\/ijms26157326","article-title":"TGF-\u03b2 signaling in cancer: mechanisms of progression and therapeutic targets","volume":"26","author":"Zbieta Cecerska-Hery\u00b4chery\u00b4c","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"19","key":"10.1016\/j.jsbmb.2025.106934_bib20","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.3390\/cancers15194689","article-title":"Estrogen receptor signaling in breast cancer","volume":"15","author":"Miziak","year":"2023","journal-title":"Cancers"},{"issue":"33","key":"10.1016\/j.jsbmb.2025.106934_bib21","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2104162118","article-title":"Drivers and suppressors of triple-negative breast cancer","volume":"118","author":"Wu","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"46","key":"10.1016\/j.jsbmb.2025.106934_bib22","doi-asserted-by":"crossref","first-page":"42908","DOI":"10.1074\/jbc.M105316200","article-title":"Cross-talk between transforming growth factor-\u03b2 and estrogen receptor signaling through Smad3","volume":"276","author":"Matsuda","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jsbmb.2025.106934_bib23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.breast.2023.07.010","article-title":"Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy","volume":"71","author":"Nordenskj\u00f6ld","year":"2023","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.jsbmb.2025.106934_bib24","first-page":"1","article-title":"TGF-\u03b2 signaling in the tumor metabolic microenvironment and targeted therapies","volume":"15","author":"Shi","year":"2022","journal-title":"J. Hematol. Oncol. 2022 151"},{"key":"10.1016\/j.jsbmb.2025.106934_bib25","article-title":"Transforming growth factor-beta (TGF-\u03b2) signaling in cancer-A betrayal within","author":"Baba","year":"2022","journal-title":"Front. Media S. A"},{"key":"10.1016\/j.jsbmb.2025.106934_bib26","unstructured":"M.A. Lynch et al., Responsiveness to Transforming Growth Factor-\u03b2 (TGF-\u03b2)-Mediated Growth Inhibition Is a Function of Membrane-Bound TGF-\u03b2 Type II Receptor in Human Breast Cancer Cells. [Online]. Available: \u3008www.cognizantcommunication.com\u3009."},{"key":"10.1016\/j.jsbmb.2025.106934_bib27","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cytogfr.2021.09.005","article-title":"Role of TGF-\u03b2 signaling in the mechanisms of tamoxifen resistance","volume":"62","author":"Babyshkina","year":"2021","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.jsbmb.2025.106934_bib28","series-title":"Routine molecular applications and recent advances in breast cancer diagnostics","author":"Pankotai-Bod\u00f3","year":"2024"},{"key":"10.1016\/j.jsbmb.2025.106934_bib29","series-title":"Molecular Mechanisms of Anti-Estrogen Therapy Resistance and Novel Targeted Therapies","author":"Ozyurt","year":"2022"},{"key":"10.1016\/j.jsbmb.2025.106934_bib30","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cytogfr.2021.09.005","article-title":"Role of TGF-\u03b2 signaling in the mechanisms of tamoxifen resistance","volume":"62","author":"Babyshkina","year":"2021","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.jsbmb.2025.106934_bib31","article-title":"TGF-\u03b2 signaling and resistance to cancer therapy","author":"Zhang","year":"2021","journal-title":"Front. Media S. A"},{"key":"10.1016\/j.jsbmb.2025.106934_bib32","article-title":"Molecular networks of FOXP family: dual biologic functions, interplay with other molecules and clinical implications in cancer progression","author":"Kim","year":"2019","journal-title":"BioMed. Cent. Ltd"},{"key":"10.1016\/j.jsbmb.2025.106934_bib33","series-title":"BioMed Central Ltd","article-title":"Novel therapies emerging in oncology to target the TGF-\u03b2 pathway","author":"Kim","year":"2021"},{"key":"10.1016\/j.jsbmb.2025.106934_bib34","series-title":"Clinical development of therapies targeting TGF\u03b2: current knowledge and future perspectives","author":"Ciardiello","year":"2020"},{"key":"10.1016\/j.jsbmb.2025.106934_bib35","article-title":"TGF-\u03b2 signaling: critical nexus of fibrogenesis and cancer","author":"Giarratana","year":"2024","journal-title":"BioMed. Cent. Ltd"},{"key":"10.1016\/j.jsbmb.2025.106934_bib36","article-title":"Novel therapies emerging in oncology to target the TGF-\u03b2 pathway","author":"Kim","year":"2021","journal-title":"BioMed. Cent. Ltd"},{"key":"10.1016\/j.jsbmb.2025.106934_bib37","article-title":"Transforming growth factor-beta (TGF-\u03b2) signaling in cancer-A betrayal within","author":"Baba","year":"2022","journal-title":"Front. Media S. A."},{"key":"10.1016\/j.jsbmb.2025.106934_bib38","article-title":"Early stage triple negative breast cancer: management and future directions","author":"Chaudhary","year":"2020","journal-title":"W. B. Saunders"},{"issue":"1","key":"10.1016\/j.jsbmb.2025.106934_bib39","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.bbrc.2018.05.139","article-title":"TGF-\u03b2 plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis","volume":"502","author":"Xu","year":"2018","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.jsbmb.2025.106934_bib40","first-page":"879","article-title":"Transforming growth factor 2: a predictive marker for breast cancer","volume":"49","author":"Dave","year":"2011","journal-title":"Indian J. Exp. Biol."},{"issue":"1","key":"10.1016\/j.jsbmb.2025.106934_bib41","doi-asserted-by":"crossref","first-page":"53","DOI":"10.5301\/JBM.2011.8736","article-title":"Prognostic utility of circulating transforming growth factor beta 1 in breast cancer patients","volume":"27","author":"Dave","year":"2012","journal-title":"Int. J. Biol. Markers"},{"key":"10.1016\/j.jsbmb.2025.106934_bib42","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ijsu.2017.07.080","article-title":"Role of transforming growth factor-\u03b21 in triple negative breast cancer patients","volume":"45","author":"Zhang","year":"2017","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.jsbmb.2025.106934_bib43","series-title":"TGF-\u03b2 at the crossroads of multiple prognosis in breast cancer, and beyond","author":"Shukla","year":"2022"},{"key":"10.1016\/j.jsbmb.2025.106934_bib44","unstructured":"K. Visvanathan et al., Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update, 2019. [Online]. Available: \u3008http:\/\/www.asco.org\/rwc\u3009."},{"key":"10.1016\/j.jsbmb.2025.106934_bib45","volume":". 01","author":"Lee","year":"2022"},{"key":"10.1016\/j.jsbmb.2025.106934_bib46","volume":". 01","author":"Hashemi","year":"2022"},{"key":"10.1016\/j.jsbmb.2025.106934_bib47","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/141747","article-title":"Two faces of TGF-Beta1 in breast cancer","volume":"2014","author":"Zarzynska","year":"2014","journal-title":"Mediat. Inflamm."}],"container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076025002626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076025002626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T22:16:31Z","timestamp":1773958591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960076025002626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":47,"alternative-id":["S0960076025002626"],"URL":"https:\/\/doi.org\/10.1016\/j.jsbmb.2025.106934","relation":{},"ISSN":["0960-0760"],"issn-type":[{"value":"0960-0760","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased TGF-\u03b2 signaling during antiestrogen therapy in triple-negative breast cancer cells","name":"articletitle","label":"Article Title"},{"value":"The Journal of Steroid Biochemistry and Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsbmb.2025.106934","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106934"}}